Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

Boehringer Mannheim Gmbh

Roche Glycart Ag

F. Hoffmann-la Roche Ag

Universitéde Liége

Zimmermann Gerd

Hans-willi Krell

Richard Endele

Pierre Bartsch

Jean-michel Foidart

Didier Cataldo

Brigitte Evrard

Luc Delattre

Hans-Willi Krell

Ernesto Menta

Valeria Lifke

Frank Grams

Birgit Bossenmaier

Gerd Zimmermann

Thomas Friess

Irene Kolm

Ekkehard Moessner

Guy Georges

Georg Fertig

Herbert Leinert

Edgar Voss

Nikolaos Dimoudis

Thomas Von Hirschheydt

Walter-Gunar Friebe

Olaf Mundigl

Elmar Bosies

Ulrich Goepfert

Michael Brandt

Fiona Grueninger

Angelika Esswein

Sonja Offner

Walter Huber

Bernd Bohrmann

Alexander Lifke

Laurence Ozmen

Sabine Woelle

Peter Rasor

Christos Tsaklakidis

Silvano Spinelli

Michael Schraeml

Anja Limberg

Jens Niewoehner

Petra Rueger

Klaus-Peter Kuenkele

Lothar Kling

Matthias Rueth

Gunter Lang

Hendrik Knoetgen

Gerhard Niederfellner

Ambrogio Oliva

Ulrich Martin

Richard Engh

Valeria Livi

Jean-Michel Foidart

Reiner Lammers

Bernhard Goller

Hans-Peter Wolff

Christian Weilke

Dirk Ponsel

Sandra Miller

Michael Schraemi

Ingo Bohn

Silvia Konetschny-Rapp

Engin Toksoez

Rolf Juchem

Georges Guy

Dagmar Geppert

Gianpiero De Cillis

Bernhard Koenig

Kairat Madin

The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Anti-HER3 antibodies and uses thereof

The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps: &#x2014;performing a first polymerase chain reaction with three to six 5'-primer and one 3&#x2032;-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5&#x2032;-primer and one 3&#x2032;-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.

Method for obtaining immunoglobulin encoding nucleic acid

An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

Use of an anti-Tau pS422 antibody for the treatment of brain diseases

The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.

Antibodies against CDCP1 for the treatment of cancer

Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.

Antibodies against human CCN1 and uses thereof

A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility.

Pharmaceutical compositions of pyrimidine-2,4,6-triones

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Phenylpyridine derivatives

The present invention relates to compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Tricycles, their manufacture and use as pharmaceutical agents

This invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and cancer related diseases.

2-(2,6-Dichlorophenyl)-Diarylimidazoles

2-(2,6-dichlorophenyl)-diarylimidazoles

Barbituric acid derivatives

3-aryl-succinamido-hydroxamic acids, methods for producing said acids and medicaments containing the same

Growing community of inventors

Penzberg, Germany

Hans-Willi Krell